Novo Nordisk has poached a top executive from AstraZeneca, tasking Ludovic Helfgott to lead development of its haemophilia and human growth hormone franchises.
Novo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate with glucose monitoring systems and glucose meters.
Novo Nordisk is laying off 400 people in Denmark and China so it can overhaul its R&D and speed up the expansion and diversification of products for serious chronic diseases.